Clinical Trials Logo

Graft-versus-host Disease (GVHD) clinical trials

View clinical trials related to Graft-versus-host Disease (GVHD).

Filter by:

NCT ID: NCT05722912 Approved for marketing - Clinical trials for Graft-versus-host Disease (GVHD)

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Start date: n/a
Phase:
Study type: Expanded Access

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

NCT ID: NCT04167514 Active, not recruiting - Clinical trials for Graft Versus Host Disease (GVHD)

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Start date: January 9, 2020
Phase: Phase 3
Study type: Interventional

Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD

NCT ID: NCT03616184 Completed - Clinical trials for Graft-versus-host-disease (GVHD)

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Start date: September 5, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to examine the efficacy of ruxolitinib in patients with sclerotic chronic graft-versus-host disease (GVHD).

NCT ID: NCT03147742 Approved for marketing - Clinical trials for Graft-versus-host Disease (GVHD)

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Start date: n/a
Phase:
Study type: Expanded Access

To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.

NCT ID: NCT03139604 Completed - Clinical trials for Graft-versus-host Disease (GVHD)

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Start date: July 19, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

NCT ID: NCT03112603 Completed - Clinical trials for Graft-versus-host Disease (GVHD)

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Start date: June 29, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

NCT ID: NCT02953678 Completed - Clinical trials for Graft-versus-host Disease (GVHD)

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Start date: December 30, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).

NCT ID: NCT02614612 Completed - Clinical trials for Graft-versus-host Disease (GVHD)

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Start date: December 2015
Phase: Phase 1
Study type: Interventional

To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).

NCT ID: NCT02167451 Terminated - Clinical trials for Graft Versus Host Disease (GVHD)

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose is to determine if the addition of Maraviroc to a standard transplant regimen will reduce the incidence of graft versus host disease in children and young adults after a stem cell transplant.

NCT ID: NCT02026934 No longer available - Clinical trials for Delayed Graft Function

CliniMACS® CD34+ Reagent System for Expanded Access Use

Start date: March 2013
Phase: N/A
Study type: Expanded Access

CliniMACs is an investigational device used to select and enrich stem cells. The device will select the stem cells with CD34+ protein. The participant will be infused with the CD34+ selected cells in the hopes that it will help the participant engraft. Engraftment is when transplanted stem cells resume production of healthy blood cells.